## Significantly Exceeding 2019 Analyst Day Targets

## One year earlier than forecasted

| Qargets |  |
| :--- | :--- |
| QCT | Revenue Growth: |
|  | Total QCT: 3-year $>10 \%$ CAGR + Apple |
|  | RF Front End: $>20 \%$ of $\$ 18 \mathrm{~B}$ SAM $(\$ 3.6 \mathrm{~B})$ in '22 |
| loT: 3-year CAGR $=10 \%$ |  |
|  | Automotive: $\$ 1.5 \mathrm{~B}$ in '24 |
|  | Operating Margin: Grow to >20\% |

FY21 Results

## Revenue Growth:

FY19-FY21 CAGR = 36\%
FY21 Revenues $=\$ 4.2 \mathrm{~B}$
FY19-FY21 CAGR $=36 \%$
FY21 Revenues $=\mathbf{\$ 9 7 5 M}$
Ahead of Schedule
FY21 Operating Margin = 29\%

```
FY21 Revenues = $6.3B
FY21 Operating Margin = 73%
```



## Other

## Note Regarding Use of Non-GAAP Financial Measures

This presentation includes "Non-GAAP financial measures" as that term is defined in Regulation G. The Non-GAAP financial measures presented herein should be considered in addition to, not as a substitute for or superior to, financial measures calculated in accordance with GAAP. Reconciliations between GAAP and Non-GAAP financial measures are provided below. Non-GAAP results exclude the QSI (Qualcomm Strategic Initiatives) segment and certain share-based compensation, acquisition-related items, tax items and other items. Other items excluded from Non-GAAP results include third-party acquisition and integration services costs and certain other items, which may include major restructuring and restructuring-related costs, goodwill and indefinite- and long-lived asset impairment charges and litigation settlements and/or damages.

## Reconciliations of GAAP to Non-GAAP Financial Measures: Opex as a Percent of Revenues

| In millions, except percentages |  | GAAP Results | Less QSI | Less Share-Based Compensation | Less Other Items ${ }^{(1)(2)}$ | Non-GAAP Results |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| FY21 | Revenues | \$33,566 | \$45 | \$- | \$54 | \$33,467 |
|  | Combined R\&D and SG\&A expenses | \$9,515 | \$16 | \$1,623 | \$161 | \$7,715 |
|  | Combined R\&D and SG\&A expenses as a percent of revenues | 28\% |  |  |  | 23\% |
| FY19 | Revenues | \$24,273 | \$152 | \$- | \$4,723 | \$19,398 |
|  | Combined R\&D and SG\&A expenses | \$7,593 | \$13 | \$1,002 | \$31 | \$6,547 |
|  | Combined R\&D and SG\&A expenses as a percent of revenues | 31\% |  |  |  | 34\% |


 and $\$ 4$ million of restructuring-related losses, partially offset by a $\$ 7$ million gain related to a favorable legal settlement.
 other items excluded from Non-GAAP combined R\&D and SG\&A were comprised of \$31 million of acquisition-related charges.

